Topic
Women's health
Evidence-based women's health and the research gaps that still matter.
This page collects every article by Dr. Damon Tojjar in this topic. For all topics see browse by topic, and for the source-anchored record see damontojjar.com/record.
Articles in this topic (14)
- Low-Dose Aspirin for Preeclampsia: Reading ASPRE and the USPSTF Recommendation
Two respected bodies of evidence point the same direction with different tools. The U.S. Preventive Services Task Force (USPSTF) gives low-dose aspirin, 81 mg daily...
- After a Dense-Breast Notification: What the DENSE Trial Actually Showed
A dense-breast notification is a fact about your mammogram, not a diagnosis or a prescription. Since September 2024, every mammography report in the United States...
- Reading Contraception Risk: Absolute Versus Relative Numbers
A newspaper can report that a contraceptive "triples" the risk of a blood clot, while a patient leaflet reports that the same method raises the yearly chance of a...
- Why Hormone Therapy Is Not Recommended to Prevent Heart Disease or Dementia
The US Preventive Services Task Force gives menopausal hormone therapy a Grade D recommendation for the primary prevention of chronic conditions, meaning it...
- HPV Self-Collection: How Its Accuracy Compares to Clinician Sampling
On validated PCR-based HPV assays, a vaginal sample a patient collects herself carries a negative predictive value close enough to a clinician-collected sample that...
- Menopause as a Metabolic Event: What the SWAN Cohort Shows About Insulin Resistance and Fat Redistribution
The menopause transition behaves like a distinct metabolic event, not simply a slice of ordinary aging. In the Study of Women's Health Across the Nation (SWAN), a...
- The 2025 Menopause Hormone-Therapy Label Reset: Which Warnings Went, Which Stayed, and Why
In November 2025 the U.S. Food and Drug Administration moved to remove the boxed warning from menopausal hormone therapy products. The change strikes the statements...
- Non-Hormonal Hot Flash Drugs: What the Trials Actually Showed
The honest bottom lineFezolinetant, sold as Veozah, is the first FDA-approved NK3-receptor antagonist for moderate-to-severe hot flashes of menopause, and the trial...
- Osteoporosis Drugs, Fracture Reduction, and the Drug-Holiday Question
Bisphosphonates lower the risk of fragility fractures, including hip fractures, and that benefit dwarfs the rare harm most people worry about: the atypical femur...
- PCOS as a Cardiometabolic Condition: What the 2023 International Guideline Recommends Testing
The 2023 International Evidence-based PCOS Guideline recognizes polycystic ovary syndrome as a cardiometabolic condition carrying elevated diabetes and...
- Sex Differences in How Drugs Work: The Ambien Dosing Story as Example and Cautionary Tale
In 2013 the U.S. Food and Drug Administration did something it had almost never done before, telling prescribers to give women half the dose of a widely used drug....
- The Women's Health Research Gap: How Women Were Left Out, and Why It Matters
For most of the twentieth century, medical research studied men and assumed the findings would transfer to women. They often did not. Women were formally...
- Reading the Women's Health Initiative Twenty Years On: Why When You Start Reframed the Debate
The 2002 Women's Health Initiative was not overturned twenty years later so much as re-read. The trial's numbers held up; what changed was the question the field...
- Why Endometriosis Takes Years to Diagnose
Endometriosis takes years to diagnose because its central symptom, pelvic pain tied to the menstrual cycle, is common, easy to normalize, and invisible on routine...